The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Stem cell mobilization with Dara-RVD induction in newly diagnosed myeloma: a real-world experience
Nisha Joseph, MD, Winship Cancer Institute, Emory University, Atlanta, GA, comments on the effectiveness of combining lenalidomide, bortezomib, and dexamethasone (RVD) with daratumumab (Dara) as induction therapy for newly diagnosed patients with multiple myeloma (MM). Based on real-world data from two institutions, this quadruplet induction regimen led to successful stem cell mobilization, with no failures and only one patient requiring a second attempt. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So this was a collaborative effort with Levine Cancer Institute and Dr Varga. And what we had done is we at our institution have been inducing newly diagnosed myeloma patients with RVD in combination with daratumumab, which is a monoclonal anti-CD38 antibody. We’ve amassed a database of a little over 300 patients, and in conjunction with Dr Varga, we had over 400 patients that we looked at...
So this was a collaborative effort with Levine Cancer Institute and Dr Varga. And what we had done is we at our institution have been inducing newly diagnosed myeloma patients with RVD in combination with daratumumab, which is a monoclonal anti-CD38 antibody. We’ve amassed a database of a little over 300 patients, and in conjunction with Dr Varga, we had over 400 patients that we looked at. And one of the challenges or one of the concerns about inducing with daratumumab in addition to RVD is are we going to be able to effectively mobilize patients’ stem cells and collect them adequately so that they can then move forward to transplant, which is ultimately the goal and the next step to try to maximize their PFS benefit.
And so when we looked across both institutions using slightly different protocols, overall generally the same, we did not see any stem cell mobilization failures. There was one patient who required a second attempt, but we did not see any failures. And I think this is really important in a real-world setting to collaborate what we’re seeing in the clinical trial setting that yes, even when we’re giving these drugs in the clinic, we’re able to collect these patients and get them successfully to transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AstraZeneca: Research Funding; Pfizer Oncology: Research Funding; GSK: Honoraria, Research Funding; BMS: Consultancy, Research Funding; J&J Oncology: Consultancy, Honoraria, Research Funding.
